|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in ratsPentadecapeptide BPC 157 resolves suprahepatic occlusion of the inferior caval vein, Budd-Chiari syndrome model in rats显示文摘BACKGROUND Recently,as a possible therapy resolving solution,pentadecapeptide BPC 157 therapy,has been used in alleviating various vascular occlusion disturbances.BPC 157 was previously reviewed as novel mediator of Robert cytoprotection and endothelium protection in the stomach,and gut-brain axis,beneficial therapy in gastrointestinal tract,with particular reference to vascular recruitment,ulcerative colitis and tumor cachexia,and other tissues healing.Here we raised new hypothesis about BPC 157 therapy in the Budd-Chiari syndrome in rats,rapid bypassing of the suprahepatic inferior caval vein occlusion,and rats recovery with the active and effective pharmacotherapy treatment.AIM To investigate Budd-Chiari syndrome model(inferior caval vein suprahepatic occlusion)resolution,since BPC 157 resolves various rat vascular occlusion.METHODS We assessed the activated bypassing pathways between the inferior and superior caval veins and portocaval shunt,counteracted caval/portal hypertension,aortal hypotension,venous/arterial thrombosis,electrocardiogram disturbances,liver and gastrointestinal lesions(i.e.,stomach and duodenum hemorrhages,in particular,congestion).Rats with suprahepatic occlusion of the inferior vena cava by ligation were medicated at 1 min,15 min,24 h,or 48 h post-ligation.Medication consisted of 10μg/kg BPC 157,10 ng BPC 157 or 5 m L/kg saline,administered once as an abdominal bath or intragastric application.Gross and microscopic observations were made,in addition to assessments of electrical activity of the heart(electrocardiogram),portal and caval hypertension,aortal hypotension,thrombosis,hepatomegaly,splenomegaly and venography.Furthermore,levels of nitric oxide,malondialdehyde in the liver and serum enzymes were determined.RESULTS BPC 157 counteracted increased P wave amplitude,tachycardia and ST-elevation,i.e.,right heart failure from acute thrombotic coronary occlusion.The bypassing pathway of the inferior vena cava-azygos(hemiazygos)vein-superior vena cava and portocaval shunt occurred rapidly.Even with severe caval portal hypertension,BPC 157 antagonized portal and caval hypertension and aortal hypotension,and also reduced refractory ascites.Thrombosis of portal vein tributaries,inferior vena cava,and hepatic and coronary arteries was attenuated.In addition,there was reduced pathology of the lungs(severe capillary congestion)and liver(dilated central veins and terminal portal venules),decreased intestine hemorrhagic lesions(substantial capillary congestion,submucosal edema and architecture loss),and increased liver and spleen weight.During the period of ligation,nitric oxide-and malondialdehyde-levels in the liver remained within normal healthy values,and increases in serum enzymes were markedly reduced.CONCLUSION BPC 157 counteracts Budd Chiari syndrome in rats. | Slaven Gojkovic Ivan Krezic Borna Vrdoljak Dominik Malekinusic Ivan Barisic andreja Petrovic Katarina Horvat Pavlov Marijan Kolovrat Antonija Duzel Mario Knezevic Katarina Kasnik Kovac Domagoj Drmic Lovorka Batelja Vuletic Antonio Kokot Alenka Boban Blagaic Sven Seiwerth Predrag Sikiric | 2020 | World Journal of Gastrointestinal Pathophysiology2020，11，1： | 2 |
| 2 | Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights显示文摘AIM To provide new insights in treatment of colitis and ischemia and reperfusion in rats using stable gastric pentadecapeptide BPC 157. METHODS Medication [BPC 157,L-NAME,L-arginine(alone/combined),saline] was bath at the blood deprived colon segment. During reperfusion,medication was BPC 157 or saline. We recorded(USB microscope camera) vessel presentation through next 15 min of ischemic colitis(ICrats) or reperfusion(removed ligations)(IC + RL-rats);oxidative stress as MDA(increased(IC-and IC + RLrats)) and NO levels(decreased(IC-rats);increased(IC + RL-rats)) in colon tissue. IC + OB-rats [IC-rats had additional colon obstruction(OB)] for 3 d(IC + OBrats),then received BPC 157 bath. RESULTS Commonly,in colon segment(25 mm,2 ligations on left colic artery and vein,3 arcade vessels within ligated segment),in IC-,IC + RL-,IC + OB-rats,BPC 157(10 μg/kg) bath(1 m L/rat) increased vessel presentation,inside/outside arcade interconnections quickly reappeared,mucosal folds were preserved and the pale areas were small and markedly reduced. BPC 157 counteracted worsening effects induced by L-NAME(5 mg) and L-arginine(100 mg). MDA-and NO-levels were normal in BPC 157 treated IC-rats and IC + RLrats. In addition,on day 10,BPC 157-treated IC + OBrats presented almost completely spared mucosa with very small pale areas and no gross mucosal defects;the treated colon segment was of normal diameter,and only small adhesions were present.CONCLUSION BPC 157 is a fundamental treatment that quickly restores blood supply to the ischemically injured area and rapidly activates collaterals. This effect involves the NO system. | Antonija Duzel Josipa Vlainic Marko Antunovic Dominik Malekinusic Borna Vrdoljak Mariam Samara Slaven Gojkovic Ivan Krezic Tinka Vidovic Zdenko Bilic Mario Knezevic Marko Sever Nermin Lojo Antonio Kokot Marijan Kolovrat Domagoj Drmic Jaksa Vukojevic Tamara Kralj Katarina Kasnik Marko Siroglavic Sven Seiwerth Predrag Sikiric | 2017 | World Journal of Gastroenterology2017，23，48： | 2 |
| 3 | Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer显示文摘 | Tanja Cufer Eduard Vrdoljak Rabab Gaafar Inci Erensoy Kristine Pemberton | 2006 | Anti-Cancer Drugs2006，，4： | 2 |
| 4 | Croatian guidelines for prevention of chemotherapy induced nausea and vomiting显示文摘 | Tomek R Vrdoljak E Vrbanec D | 2009 | Lijec Vjesn2009，131，34： | 1 |
| 5 | Optimizing treat-ment for patients with metastatic renal cell carcinoma in the Centraland Eastern European region 显示文摘 | Vrdoljak E Ciuleanu T Kharkevich G | 2012 | Expert Opin Pharmacother2012，13，2： | 1 |
| 6 | Soil aggregate hierarchy in a Brazilian oxisol显示文摘 | Vrdoljak G Sposito G | 2002 | Developments in Soil Science2002，28，： | 1 |
| 7 | Coated mi- eroneedle arrays for transeutaneous delivery of live virus vaccines 显示文摘 | VRDOLJAK A MCGRATH MG CAREY JB | 2012 | J Control Release2012，159，1： | 1 |
| 8 | Novel thiosemicarba- zone derivatives as potential antitumor agents: synthesis, physicochemical and structural properties, DNA interactions and antiproliferative activity 显示文摘 | Dilovi6 I Rub6i6 M Vrdoljak V | 2008 | Bioorg Med Chem2008，16，： | 1 |
| 9 | Randomized phase Ⅲ trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane显示文摘 | Sparano JA Vrdoljak E Rixe O | 2010 | J Clin Oncol2010，28，20： | 1 |
| 10 | Pemberton Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ ) non-small-cell lung cancer显示文摘 | Tanja Cufer Eduard Vrdoljak Rabab Gaafar | 2006 | Anti-cancer Drugs2006，17，： | 1 |
| 11 | Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice显示文摘 | Carey J B Pearson F E Vrdoljak A | 2011 | PLoS One2011，6，22： | 1 |
| 12 | Phase II , openlabel, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage III b or IV ) non-small-cell lung cancer显示文摘 | Curer T Vrdoljak E Gaafar R | 2006 | Anticaner Drugs2006，17，4： | 1 |
| 13 | Results of long-term follow-up of patients with superficial bladder carcinoma treated with intravesically applied bacillus Calmette-Guerin vaccine according to the schedule of 6 weekly + 6 monthly instillations显示文摘 | Librenjak D Situm M Vrdoljak E | 2010 | Urol Oncol2010，13，： | 1 |
| 14 | Phase Ⅱ, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲ b or Ⅳ) non small cell lung cancer显示文摘 | Curer T Vrdoljak E Gaafar R et aI | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 15 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib(IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲb or Ⅳ) non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticaneer Drugs2006，17，4： | 1 |
| 16 | Phase Ⅱ,open-label,randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage Ⅲ b or Ⅳ) non-small-cell lung cancer显示文摘 | Cufer T Vrdoljak E Gaafar R | 2006 | Anticancer Drugs2006，17，4： | 1 |
| 17 | Medial synovial plica syndrome of the knee: a diagnostic pitfall in adolescent athletes显示文摘 | Irha E Vrdoljak J | 2003 | J Pediatr Orthop B2003，12，1： | 1 |
| 18 | Expression of Ki-67 and p27(Kip1)in fine-needle aspirates from breast carcinoma and benign breast diseases显示文摘 | Ramljak V Sucˇic'M Vrdoljak DV | 2011 | Diagn Cytopathol2011，39，5： | 1 |
| 19 | Fixed-Mobile Convergence strategy:technologies and market opportunities显示文摘 | SASA IVAN VRDOLIAK | 2000 | IEEE Communications Magazine2000，38，2： | 1 |
| 20 | The impact of arehabilitation day centre program for persons suffering from schizo-phrenia on quality of life,social functioning and self-esteem 显示文摘 | Strkalj-Ivezid S Vrdoljak M Muzinic L | 2013 | Psychiatr Danub2013，25，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员